2200. Cost-effectiveness of Ceftolozane/Tazobactam for Treating Ventilated Nosocomial Bacterial Pneumonia

BACKGROUND: Ventilated, hospital-acquired and ventilator-associated bacterial pneumonia (vHABP/VABP) are associated with high rates of antibiotic resistance and high morbidity and mortality in hospitalized patients. Ceftolozane/tazobactam (C/T) has shown non-inferiority to meropenem for treating HAB...

Descripción completa

Detalles Bibliográficos
Autores principales: Naik, Jaesh, Yang, Joe, Elsea, David, Critchlow, Simone, Puzniak, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809691/
http://dx.doi.org/10.1093/ofid/ofz360.1880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809691/
http://dx.doi.org/10.1093/ofid/ofz360.1880

Ejemplares similares